Search research articles
Contact Us
Filters
Showing results (11-20 of 23) with videos related to
Page
of 3
Sort By:
European Urology
|
January 19, 2021
Significantly Minimizing Drug Wastage and the Cost of Cabazitaxel Used to Treat Metastatic Castration-Resistant Prostate Cancer
Di Maria Jiang, Nazanin Fallah-Rad, Roy Lee, et al.
BMC Family Practice
|
November 21, 2013
Improving chronic disease prevention and screening in primary care: results of the BETTER pragmatic cluster randomized controlled trial
Eva Grunfeld, Donna Manca, Rahim Moineddin, et al.
BMJ Open
|
January 10, 2020
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
Kelvin Chan, Seungree Nam, Bill Evans, et al.
Cancer Medicine
|
November 19, 2019
Are population-based patient-reported outcomes associated with overall survival in patients with advanced pancreatic cancer?
Wei Fang Dai, Jaclyn Beca, Helen Guo, et al.
JAMA Network Open
|
November 15, 2021
The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer
Michael J Raphael, William Raskin, Steven Habbous, et al.
MDM Policy & Practice
|
July 2, 2021
Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces
Reka E Pataky, Jaclyn Beca, David Tran, et al.
Leukemia & Lymphoma
|
December 6, 2018
Improved survival in overweight and obese patients with aggressive B-cell lymphoma treated with rituximab-containing chemotherapy for curative intent
James K R Stevenson, Yao Qiao, Kelvin K W Chan, et al.
International Journal of Cancer
|
October 26, 2020
Real-world, population-based cohort study of toxicity and resource utilization of second-line ipilimumab for metastatic melanoma in Ontario, Canada
Wei Fang Dai, Jaclyn Beca, Ruth Croxford, et al.
International Journal of Technology Assessment in Health Care
|
August 12, 2020
Impact of rarity on Canadian oncology health technology assessment and funding
James Keech, Wei Fang Dai, Maureen Trudeau, et al.
Cancer Medicine
|
March 31, 2023
Cost-effectiveness of second-line ipilimumab for metastatic melanoma: A real-world population-based cohort study of resource utilization
Brandon Lu, Wei Fang Dai, Ruth Croxford, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 23) with videos related to
Sort By:
Page
of 3
European Urology
|
January 19, 2021
Significantly Minimizing Drug Wastage and the Cost of Cabazitaxel Used to Treat Metastatic Castration-Resistant Prostate Cancer
Di Maria Jiang, Nazanin Fallah-Rad, Roy Lee, et al.
BMC Family Practice
|
November 21, 2013
Improving chronic disease prevention and screening in primary care: results of the BETTER pragmatic cluster randomized controlled trial
Eva Grunfeld, Donna Manca, Rahim Moineddin, et al.
BMJ Open
|
January 10, 2020
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
Kelvin Chan, Seungree Nam, Bill Evans, et al.
Cancer Medicine
|
November 19, 2019
Are population-based patient-reported outcomes associated with overall survival in patients with advanced pancreatic cancer?
Wei Fang Dai, Jaclyn Beca, Helen Guo, et al.
JAMA Network Open
|
November 15, 2021
The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer
Michael J Raphael, William Raskin, Steven Habbous, et al.
MDM Policy & Practice
|
July 2, 2021
Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces
Reka E Pataky, Jaclyn Beca, David Tran, et al.
Leukemia & Lymphoma
|
December 6, 2018
Improved survival in overweight and obese patients with aggressive B-cell lymphoma treated with rituximab-containing chemotherapy for curative intent
James K R Stevenson, Yao Qiao, Kelvin K W Chan, et al.
International Journal of Cancer
|
October 26, 2020
Real-world, population-based cohort study of toxicity and resource utilization of second-line ipilimumab for metastatic melanoma in Ontario, Canada
Wei Fang Dai, Jaclyn Beca, Ruth Croxford, et al.
International Journal of Technology Assessment in Health Care
|
August 12, 2020
Impact of rarity on Canadian oncology health technology assessment and funding
James Keech, Wei Fang Dai, Maureen Trudeau, et al.
Cancer Medicine
|
March 31, 2023
Cost-effectiveness of second-line ipilimumab for metastatic melanoma: A real-world population-based cohort study of resource utilization
Brandon Lu, Wei Fang Dai, Ruth Croxford, et al.
Page
of 3